0000000000024430
AUTHOR
Mario Federico
showing 21 related works from this author
Palliative splenic irradiation in primary and post PV/ET myelofibrosis: outcomes and toxicity of three radiation schedules
2009
Splenectomy and splenic irradiation (SI) are the sole treatment modalities to control drug resistant splenomegaly in patients with myelofibrosis (MF). SI has been used in poor surgical candidates but optimal total dose and fractionation are unclear. We retrospectively reviewed 14 MF patients with symptomatic splenomegaly. Patients received a median of 10 fractions in two weeks. Fraction size ranged from 0.2–1.4 Gy, and total dose varied from 2–10.8 Gy per RT course. Overall results indicate that 81.8% of radiation courses achieved a significant spleen reduction. Splenic pain relief and gastrointestinal symptoms reduction were obtained in 94% and 91% of courses, respectively. Severe cytopeni…
Downregulated expression of Cdc25A gene in MCF-7 breast cancer cell
2009
R-RESCOVITINE ( SELICICLIB ) INHIBITS DNA DAMAGE-INDUCED CYCLIN A! UP-REGOLATION AND HINDERS NON-HOMOLOGOUS END JOINING: A RATIONAL FOR THERAPEUTIC C…
2011
CDK-inhibitors can diminish transcriptional levels of cell cycle-related cyclins through the inhibition of E2F family members and CDK7 and 9. Cyclin A1, an E2F-independent cyclin, is strongly up-regulated under genotoxic conditions and functionally was shown to increase NHEJ activity. Cyclin A1 outcompetes with cyclin A2 for CDK2 binding, possibly redirecting its activity towards DNA repair. To see if we could therapeutically block this switch, we analyzed the effects of the CDKinhibitor R-Roscovitine on the expression levels of cyclin A1 under genotoxic stress and observed subsequent DNA damage and repair mechanisms.
BRCA1 and BRCA2 variants of uncertain clinical significance and their implications for genetic counseling
2009
Male breast cancer.
2010
Male breast cancer (MaleBC) is a rare disease, accounting for <1% of all male tumors. During the last few years, there has been an increase in the incidence of this disease, along with the increase in female breast cancer (FBC). Little is known about the etiology of MaleBC: hormonal, environmental and genetic factors have been reported to be involved in its pathogenesis. Major risk factors include clinical disorders carrying hormonal imbalances, radiation exposure and, in particular, a positive family history (FH) for BC, the latter suggestive of genetic susceptibility. Rare mutations in high-penetrance genes (BRCA1 and BRCA2) confer a high risk of BC development; low-penetrance gene mutati…
BRCA1 and BRCA2 germline mutations in sicilian breast and/or ovarian cancer families and their association with familial profiles
2009
EGF Induces STAT3-Dependent VEGF Expression in HT-29 colon cancer cells
2009
Early stage nasal vestibule tumors: safety and efficacy of HDR brachyterapy in elderly patients
2009
Seliciclib (S) Prevents Cyclin A1 DNA Damage Induced Upregulation and Reduces Double Strand Break (DSB) Repair Through NHEJ Impairment
2010
Antiemetic prophylaxis containing Palonosetron (P) alone or in combination with Aprepitant (A) in the treatment of advanced soft tissue sarcoma (STS)…
2009
Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies and Solid Tumors
2010
The human genome is epigenetically organized through a series of modifications to the histone proteins that interact with the DNA. In cancer, many of the proteins that regulate these modifications can be altered in both function and expression. One example of this is the family of histone deacetylases (HDACs), which as their name implies remove acetyl groups from the histone proteins, allowing for more condensed nucleosomal structure. HDACs have increased expression in cancer and are also believed to promote carcinogenesis through the acetylation and interaction with key transcriptional regulators. Given this, small molecule histone deacetylases inhibitors have been identified and developed…
Low dose splenic irradiation in myelofibrosis: outcomes and toxicity of three radiation schedule
2009
Nationwide interobserver variation in the diagnosis of follicular lymphoma: a report from the pathologists of GISL (Gruppo Italiano Studio Linfomi)
2005
Interobserver variability may occur in FL diagnosis, even when the diagnosis is performed by expert haematopathologists. Very limited informations are currently available on the reliability of FL diagnosis performed in laboratories on a national scale, where the lymphoma diagnosis is not always carried on by expert haematopathologists. In this study, the reproducibility of the FL diagnosis and related grading system was tested by a group of pathologists members of the Gruppo Italiano Studio Linfomi (GISL).
Splenic Irradiation (SI) in Myelofibrosis: Outcomes and Toxicity of Three Radiation Schedule
2008
R-Roscovitine (Seliciclib) prevents DNA damage-induced cyclin A1 upregulation and hinders non-homologous end-joining (NHEJ) DNA repair.
2010
Abstract Background CDK-inhibitors can diminish transcriptional levels of cell cycle-related cyclins through the inhibition of E2F family members and CDK7 and 9. Cyclin A1, an E2F-independent cyclin, is strongly upregulated under genotoxic conditions and functionally was shown to increase NHEJ activity. Cyclin A1 outcompetes with cyclin A2 for CDK2 binding, possibly redirecting its activity towards DNA repair. To see if we could therapeutically block this switch, we analyzed the effects of the CDK-inhibitor R-Roscovitine on the expression levels of cyclin A1 under genotoxic stress and observed subsequent DNA damage and repair mechanisms. Results We found that R-Roscovitine alone was unable …